Product Code: ETC070139 | Publication Date: Aug 2023 | Updated Date: Jan 2024 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 | |
The United Arab Emirates (UAE) orphan drugs market has been experiencing significant growth, driven by the increasing focus on rare diseases and personalized medicine. Orphan drugs are medications developed to treat rare medical conditions that affect a small number of patients. In the UAE, as the awareness of rare diseases grows and the government supports initiatives for rare disease management, the demand for orphan drugs has seen a surge. The market`s growth is influenced by the UAE healthcare investments, regulatory incentives for orphan drug development, and the need for improved patient outcomes in rare disease populations.
The growth of the UAE orphan drugs market is propelled by several key drivers. Firstly, the rising prevalence of rare diseases and genetic disorders has led to an increased focus on developing targeted therapies. Orphan drugs provide treatment options for conditions that were previously underserved, offering hope to patients and their families. Secondly, the UAE regulatory framework provides incentives for pharmaceutical companies to invest in orphan drug development, including extended market exclusivity and faster approval pathways. These incentives have attracted global biopharmaceutical companies to introduce their orphan drug portfolios in the UAE.
Despite the positive market outlook, the UAE orphan drugs market faces certain challenges. One significant challenge is the high cost of orphan drugs due to their limited patient populations, leading to potential affordability issues for patients and healthcare systems. Ensuring equitable access to orphan drugs for all eligible patients remains a priority for healthcare policymakers. Additionally, the limited awareness and knowledge about rare diseases among healthcare professionals and the general public may delay accurate diagnosis and treatment initiation.
The Covid-19 pandemic, which emerged in 2020, had an impact on the UAE orphan drugs market. While the pandemic initially diverted healthcare resources and attention to Covid-19 management, it also highlighted the vulnerability of patients with rare diseases. The need for continued access to orphan drugs and rare disease management remained a key focus during the pandemic, leading to increased advocacy for rare disease patients and their specific healthcare needs.
The UAE orphan drugs market is experiencing substantial growth, driven by increasing awareness of rare diseases and the need for specialized treatments. Orphan drugs, designed to treat rare medical conditions, have gained significant attention in the region, providing hope to patients and families facing these challenging health conditions. Key players at the forefront of advancing rare disease treatments in the UAE include pharmaceutical companies such as Novartis AG, Roche Holdings AG (part of Roche Group), and Sanofi S.A. These industry leaders are actively investing in research and development to develop and commercialize orphan drugs, working closely with healthcare stakeholders to improve access and affordability for patients. Additionally, local companies like Gulf Pharmaceutical Industries (Julphar) are contributing to the market`s expansion and supporting domestic research and manufacturing capabilities. As the UAE continues to prioritize rare disease management and access to orphan drugs, the orphan drugs market is set to witness further growth, fostering better outcomes for patients affected by rare medical conditions.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Arab Emirates (UAE) Orphan Drugs Market Overview |
3.1 United Arab Emirates (UAE) Country Macro Economic Indicators |
3.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, 2020 & 2027F |
3.3 United Arab Emirates (UAE) Orphan Drugs Market - Industry Life Cycle |
3.4 United Arab Emirates (UAE) Orphan Drugs Market - Porter's Five Forces |
3.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Drugs, 2020 & 2027F |
3.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Drug Type, 2020 & 2027F |
3.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume Share, By Therapy Class, 2020 & 2027F |
4 United Arab Emirates (UAE) Orphan Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 United Arab Emirates (UAE) Orphan Drugs Market Trends |
6 United Arab Emirates (UAE) Orphan Drugs Market, By Types |
6.1 United Arab Emirates (UAE) Orphan Drugs Market, By Drugs |
6.1.1 Overview and Analysis |
6.1.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Drugs, 2018 - 2027F |
6.1.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Revlimid, 2018 - 2027F |
6.1.4 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Rituxan, 2018 - 2027F |
6.1.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Opdivo, 2018 - 2027F |
6.1.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Keytruda, 2018 - 2027F |
6.1.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Imbruvica, 2018 - 2027F |
6.1.8 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Soliris, 2018 - 2027F |
6.2 United Arab Emirates (UAE) Orphan Drugs Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Biologics, 2018 - 2027F |
6.2.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Non-Biologics, 2018 - 2027F |
6.3 United Arab Emirates (UAE) Orphan Drugs Market, By Therapy Class |
6.3.1 Overview and Analysis |
6.3.2 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Oncology, 2018 - 2027F |
6.3.3 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Blood, 2018 - 2027F |
6.3.4 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Endocrine, 2018 - 2027F |
6.3.5 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Central Nervous Systems, 2018 - 2027F |
6.3.6 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Cardiovascular, 2018 - 2027F |
6.3.7 United Arab Emirates (UAE) Orphan Drugs Market Revenues & Volume, By Respiratory, 2018 - 2027F |
7 United Arab Emirates (UAE) Orphan Drugs Market Import-Export Trade Statistics |
7.1 United Arab Emirates (UAE) Orphan Drugs Market Export to Major Countries |
7.2 United Arab Emirates (UAE) Orphan Drugs Market Imports from Major Countries |
8 United Arab Emirates (UAE) Orphan Drugs Market Key Performance Indicators |
9 United Arab Emirates (UAE) Orphan Drugs Market - Opportunity Assessment |
9.1 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Drugs, 2020 & 2027F |
9.2 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Drug Type, 2020 & 2027F |
9.3 United Arab Emirates (UAE) Orphan Drugs Market Opportunity Assessment, By Therapy Class, 2020 & 2027F |
10 United Arab Emirates (UAE) Orphan Drugs Market - Competitive Landscape |
10.1 United Arab Emirates (UAE) Orphan Drugs Market Revenue Share, By Companies, 2020 |
10.2 United Arab Emirates (UAE) Orphan Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |